CHE:NYE-Chemed Corporation (USD)

COMMON STOCK | Medical Care Facilities | NYE

Last Closing Price

USD 470.81

Change

+13.80 (+3.02)%

Market Cap

USD 7.53B

Volume

0.14M

Avg Analyst Target

USD 594.50 (+26.27%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-29 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCA HCA Healthcare, Inc

+1.97 (+0.80%)

USD81.32B 16.89 10.00
FMS Fresenius Medical Care AG & Co..

+0.31 (+0.76%)

USD23.99B 18.02 9.30
AGL agilon health, inc

-0.47 (-1.24%)

USD14.81B N/A N/A
OSH Oak Street Health, Inc

+0.39 (+0.62%)

USD14.51B N/A N/A
UHS Universal Health Services, Inc

+1.07 (+0.68%)

USD13.43B 13.37 8.42
DVA DaVita Inc

+0.17 (+0.14%)

USD12.58B 18.31 10.68
EHC Encompass Health Corporation

+1.89 (+2.33%)

USD8.07B 26.62 12.04
THC Tenet Healthcare Corporation

+0.61 (+0.85%)

USD7.64B 17.76 7.31
SEM Select Medical Holdings Corpor..

+0.10 (+0.26%)

USD5.25B 16.46 10.13
AMN AMN Healthcare Services, Inc

+1.51 (+1.53%)

USD4.65B 36.70 17.62

ETFs Containing CHE

Symbol Name Weight Mer Price(Change) Market Cap
EQWM Invesco S&P MidCap Qualit.. 0.00 % 0.25 %

N/A

USD0.02B
JSMD Janus Henderson Small/Mid.. 0.00 % 0.30 %

+0.88 (+1.30%)

USD0.19B
RNMC First Trust Mid Cap US Eq.. 0.00 % 0.60 %

+0.68 (+2.38%)

USD0.02B
JELS:LSE JPMorgan ETFs (Ireland) I.. 0.00 % 0.67 %

N/A

N/A
JLSP:LSE JPMorgan ETFs (Ireland) I.. 0.00 % 0.67 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.60% 5% F 9% F
Dividend Return 0.13% 11% F 3% F
Total Return -11.48% 5% F 9% F
Trailing 12 Months  
Capital Gain -5.20% 10% F 9% F
Dividend Return 0.27% 11% F 3% F
Total Return -4.92% 5% F 9% F
Trailing 5 Years  
Capital Gain 219.97% 87% B+ 93% A
Dividend Return 4.08% 50% F 11% F
Total Return 224.05% 87% B+ 93% A
Average Annual (5 Year Horizon)  
Capital Gain 32.31% 85% B 90% A-
Dividend Return 0.45% 38% F 11% F
Total Return 32.76% 85% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 20.35% 85% B 55% F
Risk Adjusted Return 161.04% 100% A+ 99% A+
Market Capitalization 7.53B 68% D+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.45 37% F 34% F
Price/Book Ratio 8.24 35% F 12% F
Price / Cash Flow Ratio 15.39 12% F 31% F
EV/EBITDA 16.15 40% F 41% F
Management Effectiveness  
Return on Equity 40.80% 96% A 94% A
Return on Invested Capital 37.06% 100% A+ 96% A
Return on Assets 14.42% 100% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.74 83% B 57% F
Short Percent 1.12% 92% A- 75% C
Beta 0.48 81% B- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.